Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Thursday, September 5, 2024 1 min read
Key Takeaway: Lexeo Therapeutics, a clinical stage genetic medicine company, has announced its participation in several upcoming investor conferences. These include major events such as the H.C. Wainwright 26th Annual Global Investment Conference and the Baird 2024 Global Healthcare Conference. Through these presentations and webcasts, Lexeo aims to communicate its advancements in treating genetically defined cardiovascular diseases and Alzheimer’s disease associated with APOE4. The company is leveraging its pipeline of innovative programs to attract investor interest.
Market Sentiment Analysis
POSITIVE FACTORS
Lexeo Therapeutics is actively engaging with investors through multiple conferences.
The company is focused on innovative treatments for serious diseases, indicating a strong commitment to healthcare advancement.
The participation in high-profile investor conferences may enhance visibility and attract potential investments.
Full Press Release Details
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:
H.C. Wainwright 26 th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET
Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 1:25 PM ET
Cantor 2024 Global Healthcare Conference on Wednesday, September 18, 2024 at 11:30 AM ET
Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:30 PM ET
The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.